Magazine article Clinical Psychiatry News

Once-Daily Liraglutide Lowers Hb[A.Sub.1c] by 1.7% in Early Trial

Magazine article Clinical Psychiatry News

Once-Daily Liraglutide Lowers Hb[A.Sub.1c] by 1.7% in Early Trial

Article excerpt

WASHINGTON -- A new glucagonlike peptide-1 agonist known as liraglutide significantly reduced Hb[A.sub.1c] when used as monotherapy in a phase II trial that was presented at the annual scientific sessions of the American Diabetes Association.

Liraglutide, an incretin mimetic developed by Novo Nordisk A/S for once-daily injection, entered phase III testing in February.

The GLP-1 agonist exenatide (Byetta, Amylin Pharmaceuticals Inc. and Eli Lilly and Co.), approved last year by the Food and Drug Administration for use in type 2 diabetes, is administered via twice-daily injection.

Dr. Tina Vilsboll of Gentofte University Hospital in Copenhagen and her associates evaluated liraglutide in a 14-week randomized controlled trial involving 165 patients.

Liraglutide is 97% homologous to native GLP-1 but has two important alterations, she noted. These differences give the analogue a half-life of 12 hours, which makes once-daily dosing possible.

The 1-minute half-life of native GLP-1 means that, for diabetic patients, it would need to be administered via an impractical continuous pump infusion, she noted.

At the highest dose (1.9 mg), there was a mean drop in Hb[A. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.